Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Amortization - Deferred Charges Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Non-Current Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments R&D In Process Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Fennec Pharmaceuticals (FENC) Long-Term Debt Issuances (2022)

Fennec Pharmaceuticals filings provide 1 years of Long-Term Debt Issuances readings, the most recent being -$65000.0 for Q4 2022.

On a quarterly basis, Long-Term Debt Issuances changed N/A to -$65000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $19.9 million, a N/A change, with the full-year FY2023 number at $5.0 million, down 79.96% from a year prior.
Long-Term Debt Issuances hit -$65000.0 in Q4 2022 for Fennec Pharmaceuticals, down from $20.0 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $20.0 million in Q3 2022 to a low of -$65000.0 in Q4 2022.